Investigational drug · Phase 3
QMF149
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
13
Any phase or sponsor naming "QMF149"
First trial start
2023
May 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QMF149", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "QMF149" as an intervention, largest first.
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00941798 · 2,283 participants · Start Jul 2009 · Primary completion May 2011
Drug: QMF149 Twisthaler®; Mometasone Twisthaler® · For: Asthma
Sites: Birmingham, Alabama; Buena Park, California; Encinitas, California · 146 sites in all
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02554786 · 2,216 participants · Start Dec 29, 2015 · Primary completion Nov 21, 2018
Drug: Indacaterol acetate/Mometasone furoate; Mometasone furoate and 1 more · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 388 sites in all
- Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02892344 · 802 participants · Start Jan 16, 2017 · Primary completion Nov 5, 2018
Drug: QMF149 150/80 μg; MF 200 μg · For: Mild Asthma
Sites: Bulgaria, Bulgaria; Stara Zagora, Bulgaria; Pleven, Bulgaria · 123 sites in all
- Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01555151 · 739 participants · Start Jul 2012 · Primary completion Jul 2013
Drug: Mometasone furoate · For: Asthma
Sites: Kortrijk, Belgium; Liège, Belgium; Niagara Falls, Canada · 165 sites in all
- Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01636076 · 629 participants · Start Nov 2012 · Primary completion Sep 2013
Drug: QMF149; Salmeterol · For: COPD
Sites: Concord, Australia; Kogarah, Australia; New Lambton Heights, Australia · 115 sites in all
- A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With AsthmaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05562466 · 200 participants (planned) · Start May 11, 2023 · Primary completion Feb 1, 2028
Drug: QMF149; Budesonide · For: Asthma
Sites: CABA, Argentina; Mendoza, Argentina; Rosario, Argentina · 65 sites in all
- A Long-term Safety Study of QMF149 in Japanese Participants With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03100500 · 51 participants · Start Apr 25, 2017 · Primary completion Jul 19, 2018
Drug: QMF149 · For: Asthma
Sites: Nagoya, Japan; Fukuoka, Japan; Chitose, Japan · 15 sites in all
NovartisNovartis (NVS)
NCT00557440 · 37 participants · Start Nov 2007 · Primary completion Apr 2008
Drug: fluticasone propionate/salmeterol; indacaterol maleate / mometasone furoate and 2 more · For: Asthma
Sites: Aalst, Belgium; Ghent, Belgium; Berlin, Germany · 6 sites in all
NovartisNovartis (NVS)
NCT00556673 · 31 participants · Start Oct 2007 · Primary completion Apr 2008
Drug: indacaterol maleate/mometasone furoate; placebo to indacaterol maleate/mometasone furoate and 1 more · For: Asthma
Sites: Poitiers, France; Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S, Ziegler D, Tanase AM, et al. · Pulm Pharmacol Ther 2021
- Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Beeh KM, Kirsten AM, Tanase AM, et al. · Int J Chron Obstruct Pulmon Dis 2018
- Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
Vaidya SS, Khindri S, Maahs S, et al. · Clin Pharmacol Drug Dev 2016
- Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
Vaidya SS, Khindri S, Calder N, et al. · Pulm Pharmacol Ther 2016
- Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Shimada S, Vaidya S, Khindri S, et al. · Int J Clin Pharmacol Ther 2015
- Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
Beasley RW, Donohue JF, Mehta R, et al. · BMJ Open 2015
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.